It went public this May and is valued at more than $700m. Its first drug entered early clinical trials in June, aimed at treating osteoarthritis. Other startups with zombie cells in their sights include Seattle-based Oisín Biotechnologies which was founded in 2016 and has raised around $4m; Senolytic Therapeutics whose scientific development is based in Spain and which was established last September (it won’t disclose its financing other than to say it has a first round, which will allow it to reach clinical trials); and Cleara Biotech, formed this June backed by $3m in funding and based in the Netherlands. លើស ពី នេះ ទៀត, Scottish company CellAge, also founded in 2016, has raised about $100,000 to date, partly through a crowdfunding campaign.
អ្នកជក់បារីកញ្ឆារយៈពេលវែងអាចទទួលរងនូវការធ្លាក់ចុះនៅក្នុងការចងចាំពាក្យសំដីរបស់ពួកគេដោយពេលវេលាដែលពួកគេមានវ័យកណ្តាល, នេះបើយោងតាមការសិក្សាថ្មីមួយ. Appearing in JAMA Internal Medicine, ក្រដាសបង្ហាញធាតុផ្សេងទៀតនៃការយល់ដឹងអំពីរបៀប, ដូចជាល្បឿនដំណើរការនិងមុខងារប្រតិបត្តិ, ទំនងជាមិនត្រូវបានរងផលប៉ះពាល់ដោយការប្រើថ្នាំញៀន. ការស្រាវជ្រាវនេះត្រូវបានធ្វើឡើងដោយអ្នកចូលរួមស្ទង់អភិវឌ្ឍន៍ហានិភ័យនៃសរសៃឈាមអារទែបេះដូងក្នុងវ័យក (CARDIA) ការសិក្សា, ទាំងអស់នៃការនាក់ដែលមានអាយុពី 18 ទៅ 30 ក្នុងអំឡុងពេលចន្លោះពីខែមីនា 1985 និងខែមិថុនា 1986. អានអត្ថបទពេញ